Glucose Transporter-1 Cooperating with AKT Signaling Promote Gastric Cancer Progression

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28(8):1767–1775. doi:10.1093/annonc/mdx05128184417
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature1221323770567
   PubMed Web of Science ®Google Scholar
• Spencer NY, Stanton RC. The Warburg effect, lactate, and nearly a century of trying to cure cancer. Semin Nephrol. 2019;39(4):380–393. doi:10.1016/j.semnephrol.2019.04.00731300093
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.30913298683
   PubMed Web of Science ®Google Scholar
• Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3–9. doi:10.1079/BJN200276312568659
   PubMed Web of Science ®Google Scholar
• Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80(6):1046–1051. doi:10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-79305704
   PubMed Web of Science ®Google Scholar
• Amann T, Maegdefrau U, Hartmann A, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009;174(4):1544–1552. doi:10.2353/ajpath.2009.08059619286567
   PubMed Web of Science ®Google Scholar
• Martins SF, Amorim R, Viana-Pereira M, et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. BMC Cancer. 2016;16(1):535. doi:10.1186/s12885-016-2566-927460659
   PubMedGoogle Scholar
• Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92(3):634–641. doi:10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X11505409
   PubMed Web of Science ®Google Scholar
• Berlth F, Monig S, Pinther B, et al. Both GLUT-1 and GLUT-14 are independent prognostic factors in gastric adenocarcinoma. Ann Surg Oncol. 2015;22(Suppl 3):S822–831. doi:10.1245/s10434-015-4730-x26183839
   PubMedGoogle Scholar
• Schlosser HA, Drebber U, Urbanski A, et al. Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer. 2017;20(1):83–91. doi:10.1007/s10120-015-0577-x26643879
   PubMed Web of Science ®Google Scholar
• Yan S, Wang Y, Chen M, Li G, Fan J. Deregulated SLC2A1 promotes tumor cell proliferation and metastasis in gastric cancer. Int J Mol Sci. 2015;16(7):16144–16157. doi:10.3390/ijms16071614426193257
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–644. doi:10.1038/nrd292619644473
   PubMed Web of Science ®Google Scholar
• Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006;31(6):342–348. doi:10.1016/j.tibs.2006.04.00316679021
   PubMed Web of Science ®Google Scholar
• Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4):426–431. doi:10.1097/MPA.0b013e3181735ccb18953257
   PubMed Web of Science ®Google Scholar
• Gonnella R, Santarelli R, Farina A, et al. Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line. J Exp Clin Cancer Res. 2013;32:79. doi:10.1186/1756-9966-32-7924422998
   PubMed Web of Science ®Google Scholar
• Wu XL, Wang LK, Yang DD, et al. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-beta/PI3K-AKT-mTOR signaling pathway. J Cell Biochem. 2018;119(2):2356–2367. doi:10.1002/jcb.2639928884839
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou D, Shi D, et al. GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway. Biomed Pharmacother. 2019;111:993–1004. doi:10.1016/j.biopha.2019.01.01830841479
   PubMed Web of Science ®Google Scholar
• Xiao H, Wang J, Yan W, et al. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78(2):86–94. doi:10.1002/pros.2344829105798
   PubMed Web of Science ®Google Scholar
• Deng Y, Zou J, Deng T, Liu J. Clinicopathological and prognostic significance of GLUT1 in breast cancer: a meta-analysis. Medicine. 2018;97(48):e12961. doi:10.1097/MD.000000000001296130508885
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee SJ, Park SY. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Lung Cancer. 2017;104:31–37. doi:10.1016/j.lungcan.2016.12.00328212997
   PubMed Web of Science ®Google Scholar
• Sun HW, Yu XJ, Wu WC, et al. GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. PLoS One. 2016;11(12):e0168907. doi:10.1371/journal.pone.016890728036362
   PubMed Web of Science ®Google Scholar
• Ancey PB, Contat C, Meylan E. Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J. 2018;285(16):2926–2943. doi:10.1111/febs.1457729893496
   PubMed Web of Science ®Google Scholar
• Pan C, Liu Q, Wu X. HIF1alpha/miR-520a-3p/AKT1/mTOR feedback promotes the proliferation and glycolysis of gastric cancer cells. Cancer Manag Res. 2019;11:10145–10156. doi:10.2147/CMAR.S22347331819647
   PubMed Web of Science ®Google Scholar
• Schultze SM, Hemmings BA, Niessen M, Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med. 2012;14:e1. doi:10.1017/S146239941100210922233681
   PubMed Web of Science ®Google Scholar
• Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515–524. doi:10.1007/s10555-016-9637-x27896521
   PubMed Web of Science ®Google Scholar
• Salati M, Orsi G, Smyth E, et al. Gastric cancer: translating novels concepts into clinical practice. Cancer Treat Rev. 2019;79:101889. doi:10.1016/j.ctrv.2019.10188931445415
   PubMed Web of Science ®Google Scholar
• Wang S, Liu Y, Feng Y, et al. A review on curability of cancers: more efforts for novel therapeutic options are needed. Cancers (Basel). 2019;11(11):11. doi:10.3390/cancers11111782
   Web of Science ®Google Scholar
• Smyth EC, Moehler M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol. 2019;11:1758835919867522. doi:10.1177/175883591986752231489035
   PubMed Web of Science ®Google Scholar
• Vinasco K, Mitchell HM, Kaakoush NO, Castano-Rodriguez N. Microbial carcinogenesis: lactic acid bacteria in gastric cancer. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188309. doi:10.1016/j.bbcan.2019.07.00431394110
   PubMed Web of Science ®Google Scholar
• Goossens JF, Bailly C. Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396. doi:10.1016/j.pharmthera.2019.10739631356908
   PubMed Web of Science ®Google Scholar
• van Boxel GI, Ruurda JP, van Hillegersberg R. Robotic-assisted gastrectomy for gastric cancer: a European perspective. Gastric Cancer. 2019;22(5):909–919. doi:10.1007/s10120-019-00979-z31273481
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Y, Wang H. Use of immunotherapy in the treatment of gastric cancer. Oncol Lett. 2019;18(6):5681–5690. doi:10.3892/ol.2019.1093531788040
   PubMed Web of Science ®Google Scholar
• Zhao W, Jia L, Zhang M, et al. The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9(8):1846–1856.31497363
   PubMed Web of Science ®Google Scholar
• Zhu G, Foletti D, Liu X, et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci Rep. 2019;9(1):8420. doi:10.1038/s41598-019-44874-031182754
   PubMed Web of Science ®Google Scholar
• Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009;13(12):1411–1427. doi:10.1517/1472822090330750919874261
   PubMed Web of Science ®Google Scholar
• Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34(2–3):121–138. doi:10.1016/j.mam.2012.07.00123506862
   PubMed Web of Science ®Google Scholar
• Zaal EA, Berkers CR. The influence of metabolism on drug response in cancer. Front Oncol. 2018;8:500. doi:10.3389/fonc.2018.0050030456204
   PubMed Web of Science ®Google Scholar
• Wu Z, Wu J, Zhao Q, Fu S, Jin J. Emerging roles of aerobic glycolysis in breast cancer. Clin Transl Oncol. 2020;22(5):631–646. doi:10.1007/s12094-019-02187-831359335
   PubMed Web of Science ®Google Scholar
• Yan L, Raj P, Yao W, Ying H. Glucose metabolism in pancreatic cancer. Cancers (Basel). 2019;11(10):10. doi:10.3390/cancers11101460
   Web of Science ®Google Scholar
• Glenister A, Simone MI, Hambley TW. A Warburg effect targeting vector designed to increase the uptake of compounds by cancer cells demonstrates glucose and hypoxia dependent uptake. PLoS One. 2019;14(7):e0217712. doi:10.1371/journal.pone.021771231306426
   PubMed Web of Science ®Google Scholar
• Pereira-Nunes A, Afonso J, Granja S, Baltazar F. Lactate and lactate transporters as key players in the maintenance of the Warburg effect. Adv Exp Med Biol. 2020;1219:51–74.32130693
   PubMed Web of Science ®Google Scholar
• Vyas M, Patel N, Celli R, Wajapeyee N, Jain D, Zhang X. Glucose metabolic reprogramming and cell proliferation arrest in colorectal micropapillary carcinoma. Gastroenterology Res. 2019;12(3):128–134. doi:10.14740/gr114531236153
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004. doi:10.1038/nrd190216341064
   PubMed Web of Science ®Google Scholar
• Kim H, Ju JH, Son S, Shin I. Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer. FEBS Lett. 2019.
   Web of Science ®Google Scholar
• Beg M, Abdullah N, Thowfeik FS, Altorki NK, McGraw TE. Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake. Elife. 2017;6.
   Web of Science ®Google Scholar
• Zhang TB, Zhao Y, Tong ZX, Guan YF. Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45. Int J Clin Exp Med. 2015;8(2):2423–2428.25932183
   PubMed Web of Science ®Google Scholar
• Hu Y, Yang Z, Bao D, Ni JS, Lou J. miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R. Pathol Res Pract. 2019;215(12):152674. doi:10.1016/j.prp.2019.15267431732382
   PubMed Web of Science ®Google Scholar
• Siska PJ, van der Windt GJ, Kishton RJ, et al. Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J Immunol. 2016;197(6):2532–2540. doi:10.4049/jimmunol.150246427511728
   PubMed Web of Science ®Google Scholar
• Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C, Isidoro C. PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Oncotarget. 2016;7(51):84999–85020. doi:10.18632/oncotarget.1311327829222
   PubMedGoogle Scholar
• Li H, Fu L, Liu B, Lin X, Dong Q, Wang E. Ajuba overexpression regulates mitochondrial potential and glucose uptake through YAP/Bcl-xL/GLUT1 in human gastric cancer. Gene. 2019;693:16–24. doi:10.1016/j.gene.2019.01.01830690182
   PubMed Web of Science ®Google Scholar
• Lu YX, Wu QN, Chen DL, et al. Pharmacological ascorbate suppresses growth of gastric cancer cells with GLUT1 overexpression and enhances the efficacy of oxaliplatin through redox modulation. Theranostics. 2018;8(5):1312–1326. doi:10.7150/thno.2174529507622
   PubMed Web of Science ®Google Scholar